CheckMate 017 study of Opdivo (nivolumab)in squamous NSCLC success over one year-BMS
BMS announced results from CheckMate -017, a Phase III, open-label, randomized study evaluating Opdivo (n=135) versus docetaxel (n=137) in previously treated patients with advanced squamous non-small cell lung cancer. At one year, Opdivo demonstrated an overall survival rate of 42% versus 24% for docetaxel, with a median overall survival of 9.2 months versus 6 months, respectively. In the trial, Opdivo reduced the risk of death by 41%, based upon a hazard ratio of 0.59 (95% CI, 0.44-0.79; P = 0.00025). The safety profile of Opdivo in CheckMate -017 was consistent with prior studies and favorable versus docetaxel. Findings from CheckMate -017 were published in The New England Journal of Medicine and presented during an oral abstract session at the 51st Annual Meeting of the American Society of Clinical Oncology (Abstract #8009).
"The Opdivo data presented today offer patients the first major advance in the treatment of squamous non-small cell lung cancer in more than a decade,� said David Spigel, MD, Sarah Cannon Research Institute. �In this study, Opdivo not only demonstrated superior overall survival and objective response rate versus chemotherapy, the standard of care, but these benefits were sustained over time. The study also showed that squamous non-small cell lung cancer has a unique biology that resulted in similar efficacy across levels of PD-L1 expression.�..
See-
"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non�Small-Cell Lung Cancer"- Julie Brahmer, M.D., Karen L. Reckamp, M.D., Paul Baas, M.D. David R. Spigel, M.D. et., al., May 31, 2015DOI: 10.1056/NEJMoa1504627.